Advances in antiviral therapy

Current Opinion in Pediatrics

Volumn 9, Issue 1, 1997, Pages 24-30

  Dwyer, Dominic E ^a   Kesson, Alison M ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; DIDANOSINE; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; INTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VALACICLOVIR; VIDARABINE; ZALCITABINE; ZIDOVUDINE;

CYTOMEGALOVIRUS INFECTION; EPSTEIN BARR VIRUS; HEPATITIS; HERPES SIMPLEX; HERPES ZOSTER; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; VIRUS INFECTION;

EID: 0030889804     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199702000-00007     Document Type: Review

References (36)

1. Whitley RJ, Gnann JW: Acyclovir: a decade later. N Engl J Med 1992, 327:782-789.
2. Wagstaff AJ, Faulds D, Goa KL: Aciclovir: a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994, 47:153-205.
3. Wood MJ, Kay R, Dworkin BH, Soong SJ, Whitley RJ: Oral acyclovir therapy accelerates pain for resolution in patients with herpes zoster: a meta analysis of placebo controlled trials. Clin Infect Dis 1996, 22:341-347.
4. Kimberlin D, Powell D, Gruber W, Diaz P, Arvin A, Kumar M, Jacobs R, Van Dyke R, Burchett S, Soong SJ, Lakeman A, Whitley R, and the NIAID Collaborative Antiviral Study Group: Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin eyes and mouth: results of the phase I/II trials. Pediatr Infect Dis J 1996, 15:247-254. This article has preliminary evidence about the long-term use of acyclovir in neonatal herpes infections. Large series are needed.
5. Scott LL, Sanchez PJ, Jackson GL, Zeray F, Wendel GD: Acyclovir suppression to prevent cesarian delivery after first-episode genital herpes. Obstet Gynecol 1996, 87:69-73.
6. Worrall G: Acyclovir in recurrent herpes labialis [letter]. BMJ 1996, 312:6.
7. Kimberlin DW, Whitley RJ: Antiviral resistance: mechanisms, clinical significance, and future implications. J Antimicrob Chemother 1996, 37:403-421. A full review of the mechanisms of resistance of viruses to antiviral agents of clinical relevance.
8. Dwyer DE: New antiviral agents against HSV and VZV infections. Venereology 1995, 8:63-67.
9. Tyring S, Barbarash RA, Nahlik JE, Cunningham A, Marley J, Heng M, Jones T, Rey T, Boon R, Saltzman R, and the Collaborative Famciclovir Herpes Zoster Study Group: Famciclovir for the treatment of acute herpes zoster: effects on acute disease and post herpetic neuralgia. Ann Intern Med 1995, 123:89-96. The first prospective trial to show that antivirals shorten postherpetic neuralgia.
10. Degreef H and the Famciclovir Herpes Zoster Clinical Study Group: Famciclovir, a new oral antiherpes drug: result of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents 1994, 4:241-246.
11. Sacks SL, Aoki FY, Diaz-Mitoma F, Sellors J, Shafran SD: Patient initiated, plus daily oral famciclovir for early recurrence genital herpes. JAMA 1996, 276:44-49.
12. Diaz-Mitoma F, Ruben M, Sacks S, MacPherson T, Caissie G: Detection of viral DNA to evaluate outcome of antiviral treatment of patients with recurrent genital herpes. J Clin Microbiol 1996, 34:657-663.
13. Beutner KR, Fridman DJ, Forszpan IA, Andersen PL, Wood MJ: Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995, 39:1546-1553. The first paper assessing the clinical use of valaciclovir.
14. Cunningham AL, Dwyer DE: Advances and controversies in the antiviral therapy of herpes zoster. Eur J Clin Microbiol Infect Dis 1996, 15:273-275. A review of the difficulties of assessing data on new antivirals for herpes zoster.
15. Field MJ, Tewari D, Sutton D, Thackray AM: Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunocompression model. Antimicrob Agents Chemother 1995, 39:1114-1119.
16. Danner SA: Management of cytomegalovirus disease. AIDS 1995, 9(S2):53-58. A short review of a complex clinical problem.
17. Hibberd PL, Tolkoff-Rubin NE, Conti D, Stuart F, Thistlethwaite JR, Neylan JF, Snydman DR, Freeman R, Lorber MI, Rubin RH: Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients: a randomized controlled trial. Ann Intern Med 1995, 123:18-26.
18. The Oral Ganciclovir European and Australian Cooperative Study Group: Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis in patients with AIDS. AIDS 1995, 9:471-477.
19. Safrin S, Assaykeen T, Follansbee S, Mills J: Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. J Infect Dis 1990, 161:1078-1084.
20. Rahhal FM, Arevalo JF, Chavez de la Paz E, Munguira D, Azen SP, Freeman WR: Treatment of cytomegalovirus retinitis with intravitreous cidofovir in patients with AIDS. Ann Intern Med 1996, 125:98-103.
21. Davis CL, Harrison KL, McVicar JP, Forg PJ, Bronner MP, Marsh CL: Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferatlve disorder. Clin Transplant 1995, 9:53-59.
22. Connor E, Sperling R, and The Pediatric AIDS Clinical Trials Group Protocol 076 Study Group: Reduction in maternal infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994, 331:1173-1180. One of the most important published antiretroviral drug trials showing the effect of zidovudine on decreasing maternal transmission of HIV.
23. Dickover R, Garraty E, Herman S, Sims M, Plaeger S, Boyer P, Keller M, Deveikis A, Stiehm E, Bryson Y: Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. JAMA 1996, 275: 599-605. This paper identifies the factors involved in maternal transmission of HIV.
24. Fang G, Burger H, Grimson R, Troper P, Nachmans S, Mayers S, Weislow O, Moor R, Reyolt C, Hutcheon N, Weissman B: Maternal plasma HIV-1 RNA level: a determinant and projected threshold for mother-to-child transmission. Proc Natl Acad Sci U S A 1995, 92:12100-12104.
25. Saag MS, Holodniy M, Kuritzkes DR, O'Brien WA, Coombs R, Poscher ME, Jacobsen DM, Shaw GM, Richman DD, Volberding PA: HIV viral load markers in clinical practice. Nature Med 1996, 2:625-629. A review of the role of viral load testing in managing HIV.
26. Wiznia A, Crane M, Lambert G, Sanary J, Harris A, Solomon L: Zidovudine use to reduce perinatal HIV type 1 transmission in an urban medical center. JAMA 1996, 275:1504-1506. An examination of why getting HIV treatment to women who need it is difficult.
27. Matheson P, Abrams E, Thomas P, Hernan M, Thea D, Lambert G, Krasinski K: Efficacy of antenatal zidovudine in reducing perinatal transmission of human immunodeficiency virus type 1. J Infect Dis 1995, 172:353-358.
28. Brady M, McGrath N, Brouwers P, Gilbert R, Fowlers M, Yoger R, Hutton N, Bryson Y, Mithcell C, Fikrig S, Browsky W, Jiminez E, McSherry G, Rubinstein A, Wilfert C, McIntosh K, Elkins M, Weintrub P: Randomised study of the tolerance and efficacy of high-versus low-dose zidovudine in human immunodeficency virus-infected children with mild to moderate symptoms (AIDS Clinical Trial Group 128). J Infect Dis 1996, 173:1097-1106. An examination showing that dose reduction of zidovudine in children is possible.
29. Chadwick E, Nazareno L, Nieuwenhuis T, Massarella J, deDennis S, Wilkins K, Yoger R: Phase 1 evaluation of zalcitabine administered to human immunodeficiency virus-infected children. J Infect Dis 1995, 172:1475-1479.
30. Kline M, Fletcher C, Federici M, Harris A, Evans K, Rutiewicz V, Shearer W, Dunkle L: Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects. Pediatrics 1996, 97:886-890. One of the first trials of combination therapy for HIV in children.
31. American Academy of Pediatrics Committee on Infectious Diseases: Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. Pediatrics 1996, 97:137-140. Examines the reasons for less enthusiasm for ribavirin in respiratory syncytial virus.
32. Moler FW, Steinhart CM, Ohmit SE, Stidham GL for the Pediatric Critical Care Study Group: Effectiveness of ribavirin in otherwise well infants with respiratory syncytial virus-associated respiratory failure. J Pediatr 1996, 128:422-428.
33. Narkewicz M, Smith D, Silverman A, Verling J, Sokol R: Clearance of chronic hepatitis B virus infection in young children after alpha interferon therapy. J Pediatr 1995, 127:815-818.
34. Ljungman P, Andersson J, Aschan J, Bjorkstrand B, Hagglund H, Lonnqvist B, Ringden O, Winiarski J: Oral ribavirin for prevention of severe liver disease caused by hepatitis C virus during allogeneic bone marrow transplantation. Clin Infect Dis 1996, 23:167-169.
35. Fujisawa T, Inui A, Ohkawa T, Komatsu H, Miyawawe Y, Onove M: Response to interferon therapy in children with chronic hepatitis C. J Pediatr 1995, 127:660-662. Shows that interferon has a role in the management of chronic hepatitis C virus in pediatrics.
36. Torre D, Tambini R: Interferon-a therapy for chronic hepatitis B in children: a meta analysis. Clin Infect Dis 1996, 23:131-137.